Background. Widespread of the virus SARS-CoV-2 has caused development of the pandemic as called COVID-19 around the world. Clinical information shows that SARS-CoV-2 induces acute respiratory distress syndrome (ARDS), however underlying reasons for starting are unclear. Inflammatory reaction and angiogenesis are interdependent processes in a number of pathogenic desearses. Activated lymphocytes could express factor grows fibroblast-2 (FGF-2) that is able to induce angiogenesis during development of the ARDS. Besides, nitrogen oxide (NO) is produced by vascular endothelium during stimulation cytokines at the time of response against pathogenic actions SARS-CoV-2. Simultaneously, synthesis of the nitrogen oxide causes to produce and activate FGF-2 [1,2]. Our research is aimed to study the potential role of FGF-2 in pathological condition of patients suffered from COVID-19.
Methods. Plasma of the blood 60 patients was used for measurement of concentration FGF-2. 40 patients have suffered from COVID-19 including 20 patients with titer of anti-SARS-CoV-2 IgG - 5 $\pm$ 3 Index (S/C) and 20 patients with titer of anti-SARS-CoV-2 IgG – 175 $\pm$ 5 Index (S/C), in particular 20 patients without anti-SARS-CoV-2 IgG in plasma were such as control group of donors. Quantitative analysis concentration of FGF-2 was performed with the ELISA technique.
Results. Statistical analysis has revealed that concentrations of FGF-2 differed between studied groups. Thus, in patients with anti-SARS-CoV-2 IgG levels of FGF-2 were higher than in group of patients without anti-SARS-CoV-2 IgG. Nevertheless, in patients with anti-SARS-CoV-2 - 175 $\pm$ 5 Index (S/C) the mean rank of concentration FGF-2 was higher than in patients with anti-SARS-CoV-2 – 5 $\pm$ 3 Index (S/C) and the difference was significant ($H=10,14, p=0,0063$). Elevated levels of FGF2 have been caused inflammatory and hypoxia and would been implicated FGF2-induced angiogenesis during infection of SARS-CoV-2.
Conclusion. Today we don't know whether elevated FGF-2 is adaptive and beneficial characteristic for clinical situations in pathogenesis COVID-19. Further researches of dynamic changes levels of FGF-2 in patients suffered from COVID-19 can help to improve existing and to create new approaches for diagnostics of possible complications. FGF-2 could be promising target for therapia COVID-19.